Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III trial of Pimavanserin as an adjunctive treatment for Major Depressive Disorder

Trial Profile

A Phase III trial of Pimavanserin as an adjunctive treatment for Major Depressive Disorder

Planning
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2018 New trial record
    • 31 Oct 2018 According to an Acadia Pharmaceuticals media release, the company is looking forward to meet with the FDA and initiate this trial in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top